By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protein diagnostic firm Courtagen said today that it has entered into a collaboration with Avaxia Biologics to create an assay for use in developing an oral antibody therapy to mitigate the gastrointestinal damage caused by radiation exposure.

The therapy being developed is for use in radiation exposure from a nuclear incident.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.